Drug Information

Drug General Information
Drug ID
D0QY3R
Former ID
DNC006563
Drug Name
Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe
Drug Type
Small molecular drug
Indication Discovery agent Investigative [528196]
Formula
C35H56N4O9S
Canonical SMILES
CCC(C)C(C(=O)NC(CCCC(=O)OC(C)(C)C)C(=O)NC(C)C(=O)NC(CC(<br />C)C)C=CS(=O)(=O)C)NC(=O)OCC1=CC=CC=C1
InChI
1S/C35H56N4O9S/c1-10-24(4)30(39-34(44)47-22-26-15-12-11-13-16-26)33(43)38-28(17-14-18-29(40)48-35(6,7)8)32(42)36-25(5)31(41)37-27(21-23(2)3)19-20-49(9,45)46/h11-13,15-16,19-20,23-25,27-28,30H,10,14,17-18,21-22H2,1-9H3,(H,36,42)(H,37,41)(H,38,43)(H,39,44)/b20-19+/t24-,25-,27+,28-,30-/m0/s1
InChIKey
JWIOGOVPAFUFAB-OKNAZKIESA-N
PubChem Compound ID
11513217
Target and Pathway
Target(s) Cathepsin B Target Info Inhibitor [528196]
Cathepsin S Target Info Inhibitor [528196]
KEGG Pathway Lysosome
Antigen processing and presentationhsa04142:Lysosome
Phagosome
Antigen processing and presentation
Tuberculosis
NetPath Pathway TCR Signaling Pathway
IL2 Signaling PathwayNetPath_22:Leptin Signaling Pathway
IL2 Signaling Pathway
Reactome Collagen degradation
Trafficking and processing of endosomal TLR
Assembly of collagen fibrils and other multimeric structures
MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway
Degradation of the extracellular matrix
MHC class II antigen presentation
WikiPathways Class I MHC mediated antigen processing & presentation
Trafficking and processing of endosomal TLR
References
Ref 528196J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
Ref 528196J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.